Coronary Atherosclerosis Clinical Trial
— EndoGETOfficial title:
The Impact of Endothelial Function-guided Therapy Compared to Usual Care on Major Adverse Cardiovascular Events in Patients With Chest Pain and Non-obstructive Coronary Artery Disease
The current study is designed to test the hypothesis that compared to conventional treatment; endothelial function-guided treatment reduces adverse cardiovascular events in patients with non-obstructive coronary artery disease documented at clinically indicated coronary angiography.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2018 |
Est. primary completion date | June 2018 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years to 79 Years |
Eligibility |
Inclusion Criteria: - Subjects with chest pain and non-obstructive coronary artery disease documented by coronary angiography with 20-70% luminal diameter stenosis that does not justify coronary revascularization - Stable subjects without evidence of prior MI/CABG/PTCA. - Age 20 to 79 years - Ability to understand the study procedures and provide written informed consent - Willingness and ability to comply with the study and its scheduled visits and study procedures Exclusion Criteria: - Age below 20 over 79 years - Subjects with documented MI, PTCA or CABG - Unstable angina - Any lesion > 20% luminal narrowing in the left main coronary artery - Congestive heart failure, NYHA class II - IV - Severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR calculated by MDRD) < 20 mL/min/1.73m2 at screening - Uncontrolled hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) , 1.0 time the lower limit of normal (LLN) or > 1.5 times the upper limit of normal (ULN), respectively, at screening - Symptomatic peripheral artery disease - History of drug or alcohol abuse - Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) 2 times the ULN as determined by local laboratory analysis at screening - Prior CVA or TIA - Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ or stage 1 prostate carcinoma) with life expectancy of < 3 years - Any planned surgery within 3 months after randomization - Recipient of any major organ transplant (e.g., heart, lung, liver, bone marrow) - Severe, concomitant non-cardiovascular disease that is expected to reduce life expectancy to less than 3 years - Known, concerning active infection or major hematologic, renal, metabolic, gastrointestinal or endocrine dysfunction in the judgment of the investigator - Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s). Special clearance can be obtained from the Steering Committee for subjects enrolled in studies not conflicting with this protocol - History or evidence of any other clinically significant disorder, condition or disease other than those outlined above that, in the opinion of the investigator may compromise the ability of the subject to give written informed consent, would pose a risk to the subject safety, or interfere with the study evaluation, procedures or completion - Deformities of the digits of the upper extremities, which preclude adequate signal acquisition - Subjects under the effect of short-acting NTG (3 hours washout period) - Patient suffering from a medical condition prohibiting blood flow occlusion in both arms |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Israel | Meir Hospital | Kfar Saba | |
Israel | Tel Hashomer | Ramat Gan |
Lead Sponsor | Collaborator |
---|---|
Itamar-Medical, Israel |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MACE | Time to the first occurrence of death, cardiovascular death, non-fatal myocardial infarction, stroke, transient ischemic attack, coronary revascularization, or hospitalization for congestive heart failure. | 3 years | No |
Secondary | Rehospitalization for chest pain | 3 years | No | |
Secondary | quality of life questionnaire | 3years | No | |
Secondary | time to the first occurrence of cardiovascular death | 3 years | No | |
Secondary | myocardial infarction | 3 years | No | |
Secondary | Stroke | 3 years | No | |
Secondary | time to the first occurrence of death from any cause | 3 years | No | |
Secondary | hospitalization for worsening heart failure | 3 years | No | |
Secondary | time to the first occurrence of ischemic fatal or non-fatal stroke or transient ischemic attack. | 3 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02335086 -
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease
|
N/A | |
Withdrawn |
NCT02265146 -
ORACLE-NIRS: Lipid cORe Plaque Association With CLinical Events: a Near-InfraRed Spectroscopy Study
|
||
Completed |
NCT00811772 -
Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis
|
N/A | |
Recruiting |
NCT03322332 -
Adipokines of Epicardial Adipose Tissue and Atherosclerosis of Coronary Arteries
|
N/A | |
Completed |
NCT02305953 -
Cytokines and Vascular Inflammation in Psoriasis
|
N/A | |
Completed |
NCT01642173 -
Assessment of Coronary Plaque Composition Using Optical Coherence Tomography
|
Phase 1 | |
Completed |
NCT02316782 -
Bifurcation Lesion Analysis and STenting / BLAST
|
||
Completed |
NCT00548613 -
Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium
|
Phase 1 | |
Terminated |
NCT00243308 -
Serp-1 for the Treatment of Acute Coronary Syndrome
|
Phase 2 | |
Recruiting |
NCT05105750 -
A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis
|
Phase 4 | |
Completed |
NCT01722214 -
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
|
Phase 4 | |
Terminated |
NCT01030328 -
AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis
|
Phase 3 | |
Suspended |
NCT00790764 -
Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)
|
Phase 2 | |
Active, not recruiting |
NCT01061398 -
CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification
|
N/A | |
Completed |
NCT00431717 -
Coronary Computed Tomography Angiography and SPECT in Asymptomatic Diabetes
|
N/A | |
Completed |
NCT00431977 -
Validation Study of Coronary CT Angiography as a Screening Tool in Asymptomatic Diabetes
|
N/A | |
Recruiting |
NCT00155350 -
Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients
|
Phase 4 | |
Recruiting |
NCT05708547 -
Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
|
||
Terminated |
NCT02440646 -
Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
|
||
Terminated |
NCT01268319 -
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
|
N/A |